John J Minogue is a notable inventor based in Mount Vernon, NY (US). He has made significant contributions to the field of controlled release oxycodone compositions, holding a total of 4 patents. His work has focused on improving pain management through innovative pharmaceutical formulations.

Latest Patents

One of his latest patents involves a method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients. This patent discloses an oral solid controlled release dosage formulation containing from about 10 to about 40 mg of oxycodone or a salt thereof. The formulation aims to achieve a mean maximum plasma concentration of oxycodone from about 6 to about 60 ng/ml within a mean time of about 2 to about 4.5 hours after administration. Additionally, it provides a mean minimum plasma concentration from about 3 to about 30 ng/ml after repeated 'q12h' administration through steady-state conditions. Another embodiment of his patent focuses on administering an oral solid controlled release dosage formulation comprising up to about 160 mg of oxycodone, achieving a mean maximum plasma concentration of up to about 240 ng/ml.

Career Highlights

Throughout his career, John J Minogue has worked with various companies, including Euro-Celtique S.A. and Euroceltique, S.A. His innovative approaches have contributed to advancements in pharmaceutical formulations, particularly in pain management.

Collaborations

John has collaborated with notable individuals in his field, including Benjamin Oshlack and Mark Chasin. Their combined expertise has likely enhanced the development of his patented formulations.

Conclusion

John J Minogue's contributions to controlled release oxycodone compositions demonstrate his commitment to improving patient care through innovation. His patents reflect a deep understanding of pharmacology and a dedication to enhancing pain management solutions.